Spending on novel therapies in high-risk bladder cancer had minimal impact on Oncology Care Model payments to practices, according to this cohort study and an average performance estimation.
Heidi S. Wirtz, PharmD, PhD
Advertisement
Articles by Heidi S. Wirtz, PharmD, PhD
Advertisement
Latest Updated Articles
- Health Care Resource Utilization, Quality Metrics, and Costs of Bladder Cancer Within the Oncology Care Model
Published: March 16th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Biktarvy Improves ART Persistence for People With HIV and Mental Health Disorders
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Zanubrutinib Safe, Effective in Real-World CLL/SLL Cohort
5
